Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

NCT06890598 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

700

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Olomorasib
DRUG: Pembrolizumab
DRUG: Durvalumab
DRUG: Placebo

Sponsor

Eli Lilly and Company

Collaborators

[object Object]